Cours du Groupe d’Oncologie de la Société de ...splf.fr/wp-content/uploads/2016/09/Caux_GOLF-Pneumo-Sept-2016-vf.… · Immunothérapie en Cancérologie: checkpoints immunologiques

-----------------------

ImmunothérapieenCancérologie:checkpointsimmunologiquesetvoiesderecherche

---------------

ChristopheCAUX

CancerResearchCentreofLyonINSERMU1052,CentreLéonBérard

Director A. Puisieux

TeamN°11«TherapeuNctargeNngoftumorcellsandtheirimmuneenvironment»

Christophe Caux DR Inserm

CoursduGrouped’OncologiedelaSociétédePneumologiedeLangueFrancaise

(GOLF)20Septembre2016

#$$%&'"6%+8/.22,&1/!,&9!/61,-/!$/1),&.6$6!

!•! C8.9/&1/6!'>!(%$'+!.$$%&'"6%+8/.22,&1/!

•! "#$!%&&'($!)*)+$&!,)!,!-,..%$.!+/!+'&/.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!0/.&,1/(!,(2!3./4.$))%/(!

•! 5,(6$.!6$77)8!9/:!+#$*!,;/%2!%&&'($!)'.;$%77,(6$!,(2!2$)+.'61/(!

•! <&&'($!5#$6=3/%(+)!

K%$'+!

K!1/226!

EvidencesofTumorImmuno-SurveillanceinImmunocompetentMice:ExampleofIFNg1

Wildtype129/SvIFN-gR-/-

Methylcholanthrene

Methylcholanthrene-inducedtumorsinIFN-g

RK.O.mice.1

1.KaplanDHetal.PNAS.1998;95:7556-7560

EvidencesofTumorImmuno-SurveillanceinImmunocompetentMice:RoleofTcells1

1.KoebelCM,LJOld,MSmyth&SchreiberRD,Nature2007,450(7171):903-7.

0 10 20 30 100 200 300 400 500 600 700

Days

Tumorvolum

e ~20%

CarcinogeneLowdose

a-CD4,a-CD8a-IFN-g

EvidencesofTumorImmuno-SurveillanceinHuman:IncreasedCancerIncidenceinImmuno-DepressedTransplantedPaNents1

1.Birkeland,IntJCancer199530:183-9.

TumorSite RaNo

Skin(non-melanoma) 24.7

Thyroid 14.3

Endocrinesystem 13.8

ORL 10.8

Vulva,vagina 10.3

Non-HodgkinLymphoma

9.1

Kidney 5.5

Colorectal 3.6

Lung 2.4

Brain 2.4

Prostate 2.1

Melanoma 1.7

EffectorMemoryTCellsInfiltraNonPredictSurvivalinColorectalCancer1

1.PagesFetal.NEnglJMed.2005;353:2654–2666.2.GalonJetal.Science2006;313:1960–64.

ImmunogenicCellDeathinCancerTherapy

MichaudM,KroemerG.Science.2011;334:1573-7.KroemerG,ZitvogelL.AnnuRevImmunol.2013;31:51-72.

#$$%&'"6%+8/.22,&1/!,&9!/61,-/!$/1),&.6$6!

!•! X;%2$(6$)!/0!+'&/.!%&&'(/H)'.;$%77,(6$!

•! K)/!.$$%&/!6@6(/$!,6!,!W,++./+!('!(%$'+!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!>'+$,N'&!,&9!-+'3+/66.'&!

•! 5,(6$.!6$77)8!9/:!+#$*!,;/%2!%&&'($!)'.;$%77,(6$!,(2!2$)+.'61/(!

•! <&&'($!5#$6=3/%(+)!

K%$'+!

K!1/226!

e/$,('-'./N1!B(/$!1/22!

A]!1/226!

D,1+'-),3/6!

_/&9+.N1!1/226!

J!1/226!

K!1/226!

Z@!`!(,+'.,7!=%77$.?!>?!Z/.;$77!a?!<(8![.$(2$.4,)+!^5!$+!,7?!/'-0+*&,::)-;(<+*'=>?!R(2!$2?!X7)$;%$.D!RI>V8>>]RS?!

#&&,(/!#$$%&.(@!

5,(!.$6/4(%b$!(,1;$!)+.'6+'.$)!+#./'4#!)/&,16!$(6/2$2!.$6$3+/.)!0./&!

3,+#/4$()!,(2!(,)6$(+!+'&/.!6$77)!,(2!2$)+./*!

+#$&! D,1+'-),3/6!

J'()!#&&,(/!,&9!:9,-N8/!:+$6!'>!K)/!#$$%&/!B@6(/$!0,&!T.3)(!K%$'+6!

Q$6/4(%b$!,(2!$.,2%6,+$!3,+#/4$()!,(2!(,)6$(+!+'&/.!6$77)!+#./'4#!+#$%.!,(14$(!.$6$3+/.!"5Q!P!W5Q!T#%4#!2%;$.)%+*!2'$!

+/!4$($16!.$6/&-%(,1/(U!

:9,-N8/!#$$%&.(@!

TheInnateImmuneSystemFightTumorsViaaVarietyofFuncNonallySpecializedCells1

NK=naturalkiller.1.NorvellA.In:PrendergastGCetal.CancerImmunotherapy.2nded.Elsevier;2013:11–24.

Destruc1onofInfectedcellsbyCytotoxicity,PhagocytosisorAn1bodyDependentCellCytotoxicity

B'$/!K%$'+!0/226!CY-+/66!D%2N-2/!:&N3/&6!K),(!:+/!A'(!CY-+/66/9!W@!A'+$,2!0/226E!

>?!\%((!NM?!"&1-23&.&4+5?!RIICDVEC8RFIS]RF>E?!

K%$'+!1/226!/Y-+/66\+/2/,6/!,W&'+$,2!6/2>!,&N3/&6!(),(!1,%6/!()/$!('!W/!+/1'3&.i/9!,6!

>'+/.3&!/&NN/6!,&9!()/+/>'+/!/2.1.(!,&!.$$%&/!+/6-'&6/^!

A'+$,2!1/226!/Y-+/66\+/2/,6/!$'2/1%2/6!(),(!9'&Q(!/2.1.(!,&!.$$%&/!+/6-'&6/!U('2/+,&1/!('!

&'+$,2!6/2>V^!

AR=D:?!0C??! K;DR=!0C??!

MutaNonalHeterogeneityinCancerCreatesTherapeuNcChallengesandOpportuniNes

AlteredproteinscontainnewepitopesforimmunerecogniNon,providingacommondenominaNonforimmunotherapy

TUMOR

>?!J,*!@\!M.!$+!,7?!<(8![.$(2$.4,)+!^5!$+!,7?!/'-0+*&,::)-;(<+*'=>?!R(2!$2?!X7)$;%$.D!RI>V8>I>]>>V?!

1. Antigens are released by tumor cells and captured by dendritic cells.

Dendritic cell

K!1/226!:+/!#$-'+(,&(!.&!()/!:W.2.(@!'>!()/!#$$%&/!B@6(/$!('!_/(/1(!,&9!_/6(+'@!K%$'+!0/226E!

_0!&/(b'+5!.&!65.&!

TUMOR 2. Dendritic cells activate naive T cells in lymph

nodes.


Dendritic cell

LYMPH NODE

Naive T cell

LYMPH

>?!J,*!@\!M.!$+!,7?!<(8![.$(2$.4,)+!^5!$+!,7?!/'-0+*&,::)-;(<+*'=>?!R(2!$2?!X7)$;%$.D!RI>V8>I>]>>V?!

K!1/226!:+/!#$-'+(,&(!.&!()/!:W.2.(@!'>!()/!#$$%&/!B@6(/$!('!_/(/1(!,&9!_/6(+'@!K%$'+!0/226E!

TUMOR

3. Activated T cells migrate back to the tumor.

2. Dendritic cells activate naive T cells in lymph

nodes.


Activated T cell

Dendritic cell

LYMPH NODE

Naive T cell

LYMPH

>?!J,*!@\!M.!$+!,7?!<(8![.$(2$.4,)+!^5!$+!,7?!/'-0+*&,::)-;(<+*'=>?!R(2!$2?!X7)$;%$.D!RI>V8>I>]>>V?!

K!1/226!:+/!#$-'+(,&(!.&!()/!:W.2.(@!'>!()/!#$$%&/!B@6(/$!('!_/(/1(!,&9!_/6(+'@!K%$'+!0/226E!

TUMOR

4. T cells kill tumor cells through the release of lytic enzymes or

induction of apoptosis.

3. Activated T cells migrate back to the tumor.

2. Dendritic cells activate naive T cells in lymph

nodes.


Activated T cell

Dendritic cell

LYMPH NODE

Naive T cell

LYMPH

1. Antigens are released by tumor cells and

K%$'+!

K!1/226!

>?!J,*!@\!M.!$+!,7?!<(8![.$(2$.4,)+!^5!$+!,7?!/'-0+*&,::)-;(<+*'=>?!R(2!$2?!X7)$;%$.D!RI>V8>I>]>>V?!

K!1/226!:+/!#$-'+(,&(!.&!()/!:W.2.(@!'>!()/!#$$%&/!B@6(/$!('!_/(/1(!,&9!_/6(+'@!K%$'+!0/226E!

K"0/22!:1N8.(@!#6!=/3%2,(/9!J@!#$$%&/!0)/15-'.&(6!('!?.$.(!:%('.$$%&.(@E!!

TUMOR

5"LaHS!`!6*+/+/c%6!"H7*&3#/6*+$!,(14$(!SD![AH>!`!3./4.,&&$2!6$77!2$,+#!3./+$%(!>D!La^HV!`!7*&3#/6*+$!,61;,1/(!4$($!VD!"<JHV!`!"H6$77!%&&'(/47/-'7%(!,(2!&'6%(!3./+$%(!V?!>?![,.2/77!AJ?!"'(&8+9&/'-0+*?!RI>RD>R8RERHRGS?!!!

Activated T cell

Immune checkpoints, such as CTLA-4, PD-1, LAG-3, and TIM-3 function at

different phases in the immune response to regulate the duration and level of the T-

cell response.

Checkpoints

TUMORCheckpoints H H

Inactivated T cell

Inactivated T cell

LYMPH NODE

Dendritic cell

HH

#$$%&'"6%+8/.22,&1/!,&9!/61,-/!$/1),&.6$6!

!•! X;%2$(6$)!/0!+'&/.!%&&'(/H)'.;$%77,(6$!

•! "#$!%&&'($!)*)+$&!,)!,!-,..%$.!+/!+'&/.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!0/.&,1/(!,(2!3./4.$))%/(!

•! 0,&1/+!1/2264!e'b!()/@!,8'.9!.$$%&/!6%+8/.22,&1/!,&9!9/6(+%1N'&!

•! <&&'($!5#$6=3/%(+)!

K%$'+!

K!1/226!

K%$'+!/61,-/!$/1),&.6$6!

>?!A.,=$!5^K!$+!,7?!#59!,::)-;3?!RIIGDBI8E>]C>D!R?!Y$)$7*!JAK!$+!,7?!#--)&8+9&,::)-;3?!RI>>DRB8RVE]RF>?!!!

U/3I!K+/36V!

U/3I!KPT"JV!

U/3I!9'b&!+/3%2,N'&!'>!De0!#V!

U/3I!9.6+%-N'&!'>!K"1/22!1)/15-'.&(!-,()b,@6V!

#&).W.N'&!'>!(%$'+!,&N3/&!-+/6/&(,N'&!

E

B/1+/N'&!'>!.$$%&'6%--+/66.8/!>,1('+6!

H

#&).W.N'&!'>!,j,15!W@!.$$%&/!1/226!

c

=/1+%.($/&(!'>!.$$%&'6%--+/66.8/!1/22!

(@-/6!

k

:S0!K%$'+!0/22!

K"+/3!:1N8,(/9!K"

1/22!

>B!

K%$'+!/61,-/!$/1),&.6$6!


U/3I!K+/36V!

U/3I!KPT"JV!

U/3I!9'b&!+/3%2,N'&!'>!De0!#V!

U/3I!9.6+%-N'&!'>!K"1/22!1)/15-'.&(!-,()b,@6V!

#&).W.N'&!'>!(%$'+!,&N3/&!-+/6/&(,N'&!

E

B/1+/N'&!'>!.$$%&'6%--+/66.8/!>,1('+6!

H

#&).W.N'&!'>!,j,15!W@!.$$%&/!1/226!

c

=/1+%.($/&(!'>!.$$%&'6%--+/66.8/!1/22!

(@-/6!

k

:S0!K%$'+!0/22!

K+/3!:1N8,(/9!K"

1/22!

RI!

MHC II

TCR

Adapté de : Wood, K.J. and Sakaguchi, S. (2003) Nat Rev Immunol 3, 199-210

conventional T cell

=/3%2,('+@!K!2@$-)'1@(/6!UK+/3V!.&).W.(!1'&8/&N'&,2!K!1/22!,1N8,N'&!

!! Involved in auto-immunity

!! Contributing to tumor development

-! Increase Treg frequency in blood of patients suffering from different cancer types (Udaya 2002, Wolf 2003)

- Negative Impact on patients survival in

ovarian cancer (Curiel 2004)

k^!=/1+%.N&3!#$$%&'6%--+/66.8/!0/226!4!./!K+/3!CY-2'.N&3!#$$%&/!K'2/+,&1/!S,()b,@6!

RegulatoryTcell(Treg)InfiltraNonIsaBadPrognosisFactorinOvarianTumor

Curiel.NatMed.2004;10:942.

Allstages

StagesIII StagesIV

S2,6$,1@('.9!_/&9+.N1!0/226!U-_0V!,&9!K+/3!,(!()/!0/&(/+!!

'>!#$$%&'6%--+/66.8/!A/(b'+56!.&!J+/,6(!K%$'+6!!

E?!^/-$.+!JK!/'-0+*&8+?@&RIIBD!H?!Jd(d+.%$.H5,'c!5K!/'-0+*&8+?@&RIIBD!k?!\,4$+!MK!Jd(d+.%$.H5,'c!5@&/'-0+*&8+?@&RI>>D!c?!L,-%2%H^,7*!W$(2.%))HY$.&,.$!Z@&/'-0+*&8+?&RI>>D!G?!\,4$+!MK!Jd(d+.%$.H5,'cK!/'-0+*&8+?@&RI>RD!X?!O%)%.,=!YK!W$(2.%))HY$.&,.$!Z@&/'-0+*&8+?&RI>RD!l?!O%)%.,=!YK!W$(2.%))HY$.&,.$!ZK!,-(&.&/'-0+*&RI>VD!d?!L$!J$.6%$.!<K!['%)%$'c!<K!^/'+,4(*!Z@&/'-0+*&8+?&RI>V!

e!,7%;$!3,

1$(+)!

I!

IKR!

IKS!

IKG!

IKC!

>KI!

K+/3).3)!

K+/3?'b!

I! RI! SI! GI! CI! >II!

R8/+,22!B%+8.8,2!

D'&()6!>+'$!9.,3&'6.6!

HFY!cFY!

-_0\K+/3!

R8/+,22!B%+8.8,2!e!,7%;$!3,

1$(+)!

PDC -

PDC +

D'&()6!>+'$!9.,3&'6.6!80 60 40 20 0

1,0 ,9 ,8 ,7 ,6 ,5 ,4 ,3 ,2 ,1

0,0 -!m!F^FFFE! U&mHGFV!

>?!^/-$.+!JK!/'-0+*&8+?@&RIIBD!R?!Jd(d+.%$.H5,'c!5K!/'-0+*&8+?@&RIIBD!V?!\,4$+!MK!Jd(d+.%$.H5,'c!5@&/'-0+*&8+?@&RI>>D!S?!L,-%2%H^,7*!W$(2.%))HY$.&,.$!Z@&/'-0+*&8+?&RI>>D!E?!\,4$+!MK!Jd(d+.%$.H5,'cK!/'-0+*&8+?@&RI>RD!G?!O%)%.,=!YK!W$(2.%))HY$.&,.$!Z@&/'-0+*&8+?&RI>RD!F?!O%)%.,=!YK!W$(2.%))HY$.&,.$!ZK!,-(&.&/'-0+*&RI>VD!C?!L$!J$.6%$.!<K!['%)%$'c!<K!^/'+,4(*!Z@&/'-0+*&8+?&RI>V!

X3%+#$7%,7!"'&/.!

KPT!

pDC

"!5$77!Xf$6+/.)!

+

X3%+#$7%,7pDC : plasmacytoïd DC

+ CD8

CD4

Treg

Treg

Treg

Treg

#TA"

#?"EF+ ICOS

S2,6$,1@('.9!_/&9+.N1!0/226!U-_0V!,&9!K+/3!,(!()/!0/&(/+!!

'>!#$$%&'6%--+/66.8/!A/(b'+56!.&!J+/,6(!K%$'+6!!

K%$'+!/61,-/!$/1),&.6$6!


U/3I!K+/36V!

U/3I!KPT"JV!

U/3I!9'b&!+/3%2,N'&!'>!De0!#V!

U/3I!9.6+%-N'&!'>!K"1/22!1)/15-'.&(!-,()b,@6V!

#&).W.N'&!'>!(%$'+!,&N3/&!-+/6/&(,N'&!

E

B/1+/N'&!'>!.$$%&'6%--+/66.8/!>,1('+6!

H

#&).W.N'&!'>!,j,15!W@!.$$%&/!1/226!

c

=/1+%.($/&(!'>!.$$%&'6%--+/66.8/!1/22!

(@-/6!

k

:S0!K%$'+!0/22!

K"+/3!:1N8,(/9!K"

1/22!

RE!

S_"E\S_"?E!

#$$%&'"6%+8/.22,&1/!,&9!/61,-/!$/1),&.6$6!

!•! X;%2$(6$)!/0!+'&/.!%&&'(/H)'.;$%77,(6$!

•! "#$!%&&'($!)*)+$&!,)!,!-,..%$.!+/!+'&/.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!0/.&,1/(!,(2!3./4.$))%/(!

•! 5,(6$.!6$77)8!9/:!+#$*!,;/%2!%&&'($!)'.;$%77,(6$!,(2!2$)+.'61/(!

•! #$$%&/!0)/15-'.&(6!

K%$'+!

K!1/226!

ImmuneCheckpoints•  Checkpointpathways

–  CTLA-4andPD-1•  OtherCheckpoints:B7familyandothers•  BeyondCheckpoints:Cos1mulators•  BeyondTcells:NK,DC,Macrophage•  Markersforcheckpointpathwayinhibi1on

<&&'($!5#$6=3/%(+)!

[,.2/77?!"'(&8+9&/'-0+*%&AI>R?!

\,&%77$!WF!

\,&%77$!"Z\!

GJFreeman&AHSharpe.NatImmunol.2012.

TumorInfiltraNngLymphocytesExpressMulNpleImmunoinhibitoryReceptors

Thesearedruggabletargetsfortumorimmunotherapy

Signal1

Signal2

CTLA-4andPD-1PathwayInhibitsTCellResponses

GFreeman2008;PNAS105:10275

#-.2.$%$,W!U:&N"!0K?:cV!#$-+'8/!?'&3!K/+$!B%+8.8,2!.&!D/(,6(,N1!D/2,&'$,!

<3%7%&'&,-!37')!2,6,.-,b%($!0/.!3.$;%/')7*!'(+.$,+$2!&$+,)+,16!&$7,(/&,?>!!

<&3./;$2!)'.;%;,7!:%+#!%3%7%&'&,-!%(!3,1$(+)!:%+#!&$+,)+,16!&$7,(/&,?!R!

>?!Q/-$.+!5K!"#/&,)!LK!$+!,7?!"&1-23&.&4+5?!RI>>D!VGS8RE>FHRG?!R?!9/2%!\OK!NgA,*!OMK!$+!,7?!"&1-23&.&4+5%&RI>ID!VGV8F>>HRV!

AnN-CTLA4ofIgG2aisotypeEnhanceAnNtumorAcNvityThroughDepleNonofIntratumoralTregs

SelbyMJ&KormanAJ.CancerImmunolRes.2013;1:32-42.

Fc-DependentDepleNonofTumorInfiltraNngTregco-DefinestheEfficacyofanN-CTLA4Therapy

SimpsonTR&QuezadaA.JExpMed.2013;210:1695-710.

GJFreeman&AHSharpe.NatImmunol.2012.

TumorInfiltraNngLymphocytesExpressMulNpleImmunoinhibitoryReceptors

Thesearedruggabletargetsfortumorimmunotherapy

PotentTherapeuNcEfficacyofPembrolizumab(anN-PD1MSD)inMelanoma

HamidO.NEJM.2013.

N=135,13%grade3/4toxicity

53%objec1veResponses

RibasA.NEnglJMed.2012;366:2517-2519.

DifferencesBetweenBlockingCTLA4/B7andBlockingPD-1/PD-L1

TumorAnNgen–SpecificCD8TcellsInfiltraNngtheTumorExpressHighLevelsofPD-1andAreFuncNonallyImpaired

TumorinfiltraNngTcellsupregulatePD1 PD1expressingTcellsaredysfuncNonal

AhmadzadehM&RosenbergSA.Blood.2009;114:1537-44

PD-L1:B7-1PathwayAlsoInhibitsTCellResponses

•  B7-1interactsmorestronglywithPD-L1(1.7μM)thanwithCD28(4μM)butlessstronglythanwithCTLA-4(0.2μM)

•  Alltherapeu1cPD-L1Absaredualblockers•  B7-1:PD-L1interac1oninhibitsTcellresponsespredominantroleincontrollingeffectorTcellresponses

Bule,etal.Immunity.2007.Paterson,etal.JI.2011.

AnN-PD-1andAnN-PD-L1mAbsBlockDisNnctInteracNons

AnN-PD-1andAnN-PD-L1mAbsBlockDisNnctInteracNons



R()/+!#$$%&/!0)/15-'.&(6!

[,.2/77?!"'(&8+9&/'-0+*%!RI>R?!

Jl!>,$.22@!

?:PkI!K#DkI!p!

•  Igsuperfamilymember•  BindsMHCclassII(likeCD4)•  ExpressedbyacNvatedTcells•  LAG-3ligaNoninhibitsTCRsignaling•  AlsoexpressedbyTregs.BlockingofLAG-3resultsininhibiNonofsuppressivecapacity

•  AcNvaNonofCD8+TcellsleadstoLAG-3upregulaNon•  LAG-3mayrenderCD8+Tcellsinatolerogenicstate•  CombinedanN-PD1andanN-LAG-3mayhavebejeranN-tumoreffects

LAG-3(lymphocyteacNvaNongene-3)

TIM-3(Tcellimmunoglobulin-3)•  IgsuperfamilymemberconsistsofanN-terminalIgV

domainandamucindomain•  Tim-3ligand:S-typelecNngalecNn-9(Gal-9),soluble

moleculewidelyexpressed,upregulatedbyIFN-γ•  Tim-3asanegaNveregulatorymolecule:negaNve

regulatorofIFN-g-secreNngCD4+Thelper1andCD8+Tcytotoxic1cells

•  PromotedevelopmentofCD8+TcellexhausNon•  Invivoblockaderesultsinexacerbatedautoimmunityand

abrogaNonoftoleranceinexperimentalmodels,•  Induceexpansionofmyeloid-derivedsuppressorcells

(MDSC),expressinghighlevelsofGla-9•  TumorinfiltraNnglymphocytesco-expressedPD-1and

TIM-3

SakuishiK,TrendsImmunol.2011;32:345-9AndersonAC.CurrOpinImmunol.2012;24:213-6

NewCombina1onImmunotherapies:

•  An1-PD1/PDL1+an1-LAG3•  An1-PD1/PDL1+an1-TIM-3•  An1-PD1+agonis1can1-GITR•  An1-PD1+otheragonis1can1bodies•  Triplecombina1ons?(an1-CTLA4+an1-PD1+3rdnewdrug)

WooSetal.CancerRes.2012;72:917-927.

AnN-LAG-3+AnN-PD-1

CombinatorialanN–LAG-3/anN–PD-1TreatmentInhibitsTumorGrowth

EffectofTargeNngtheTim-3andPD-1SignalingPathwaysonTumorGrowth.

Sakuishi K et al. J Exp Med 2010;207:2187-2194

CT26 tumor cells implanted into wild-type BALB/c mice.

W7,(=!5pK!/)**+-(&E=&E-0;3%&AFGH%!

#$$%&/!0)/15-'.&(!S,()b,@6!.&!12.&.1,2!(+.,26!


–  CTLA-4andPD-1•  OtherCheckpoints:B7familyandothers•  BeyondCheckpoints:CosNmulators•  BeyondTcells:NK,DC,Macrophage•  Markersforcheckpointpathwayinhibi1on

W7,(=!5p?!/)**+-(&E=&E-0;3%!RI>S?!

#$$%&/!0'6N$%2,N'&!S,()b,@6!.&!02.&.1,2!K+.,26!

S'6.N8/!0'6N$%2,N'&!S,()b,@6!!

\,&%77$!"Z\!

TcellTargetsforImmunoregulatoryAnNbodyTherapy

Mellmanetal.Nature.2011;480,480-489.

BMS-663513

• BMS-936558• CT011• MK-3475SCH900475

AnNPDL-1BMS-936559

TRX518

AgonistanN-OX40

ICOS ICOS

Ipilimumab

BeyondCheckpoints:GITRCo-sNmulaNon

•  GITR(Glucocor1coid-InducedTumornecrosisfactor-relatedReceptor)iscons1tu1velyexpressedathighlevelsonTregsandatlowonres1ngCD4+andCD8+Tcells,andNKcellss1,2

•  GITRexpressionishighlyupregulatedonac1vatedCD4+andCD8+TcellsandNKcells,includingtumorinfiltra1nglymphocytes

•  GITRmodula1onhasbeenindicatedasoneofthetop25mostpromisingresearchareasbytheAmericanNa1onalCancerIns1tute,andclinicaltrialsstarted2

•  GITRliga1onbyGITRL(oran1-GITRagonistan1bodies)providesacos1mulatorysignalthatenhancesbothCD4+andCD8+Tcellprolifera1onandeffectorfunc1onsleadingtoenhancedcellularandhumoralimmunity

•  Inaddi1on,cos1mula1onthroughGITRhasbeenshowntorendernaiveoreffectorTcells(Teffs)resistanttothesuppressiveeffectsofTregs

•  Incontrast,blockingGITR-GITRLsignalingwithantagonistan1-GITRLan1bodiesinhibitsTlymphocyteac1va1on

1.  Mouseglucocor1coid-inducedtumornecrosisfactorreceptorligandiscos1mulatoryforTcells.Tone,M.,Tone,Y.,Adams,E.,Yates,S.F.,Frewin,M.R.,Cobbold,S.P.&Waldmann,H.(2003)Proc.Natl.Acad.Sci.USA100,15059–15064

2.  Pharmacologicalmodula1onofGITRL/GITRsystem:therapeu1cperspec1ves.GiuseppeNocen1ni,SimonaRonches,MariaGraziaPetrilloandCarloRiccardiBri1shJournalofPharmacology(2012)1652089–20992089

BeyondCheckpoints:CD137/4-1BBCo-sNmulaNon

•  CD137/4-1BB,memberoftheTNFreceptorsuperfamilyTcellcos1mulatoryreceptor,isinduced,whenTcellsreceivean1gen-specificsignals

•  SignalsviaCD137/4-1BBarecos1mulatoryinnature•  CD137/4-1BBsignalingbyan1-4-1BBac1vatesvariousimmunecompetentcells,

includingTandNKcells,andAPCs,leadingtoac1va1on,cytokineinduc1on,upregula1onofCTLac1vity,andincreasedsurvival

•  Signalsthrough4-1BBaremorebiasedtowardCD8+TcellsandNKcells,bothinvitro,andinvivo

•  Invivoadministra1onofagonis1can1-CD137/4-1BBintomicepromoteCD8+Tcellexpansion,andprotectagainstseveralpathologicalcondi1ons,includingautoimmunity,cancer,andtransplanta1on.Thereasonsunderlyingtheinvitrovs.invivofunc1onsofan1-4-1BBarecurrentlyunclear.

•  Targe1ngCD137/4-1BBeitherbyan1-4-1BBalone,orincombina1onwithotheragents,haspowerfulan1cancerproper1es.

•  AfullyhumanIgG4an1-CD137an1bodyisunderdevelopmentwithsignsofclinicalac1vityanddose-dependenteffects.

VinayDS,KwonBS.4-1BB(CD137),aninduciblecos1mulatoryreceptor,asaspecifictargetforcancertherapy.BMBRep.2014Mar;47(3):122-9.AsciertoPA,SimeoneE,SznolM,FuYX,MeleroI.Clinicalexperienceswithan1-CD137andan1-PD1therapeu1can1bodies.SeminOncol.2010Oct;37(5):508-16.



J/@'&9!K!0/2264!A]I!_0I!D,1+'-),3/!

Z@!5$77!A5iJ#!5ASF!5ASF!5ASF!5ASF!5ASF! A5iJ

Immuno-modulation des lymphocytes NK

Innate-pharma.com 57

Kandalau.JClinOncol.2011.

AnN-CD40toSNmulateDCandInducedAnN-TumorImmunity

AnN-CD40mAbinduceobjecNveresponses(20%)inpancreaNcandovariancancers

BealyGL,Science2011

PancreaNccancer

VonderheideRH,Oncoimmunology2013

PR,N=6(20%)1Ovariancancer

PR,N=5(20%)

Ovariancancers

Blockthe“Don’tEatMe”Signal

HouotR,KohrtHE,MarabelleA,LevyR.Targe1ngimmuneeffectorcellstopromotean1body-inducedcytotoxicityincancerimmunotherapy.TrendsImmunol.2011;32:510-6.

AnN-tumormAb+anN-CD47:BoostMacrophagesAnNbodyDependentCellPhagocytosis(ADCP)

AnN-CD47mAbSynergizeswithRituximabtoPromotePhagocytosisandEradicateNon-HodgkinLymphoma.

ChaoMP,&,LevyR,WeissmanIL,Maje1R.An1-CD47an1bodysynergizeswithrituximabtopromotephagocytosisanderadicatenon-Hodgkinlymphoma.Cell.2010Sep3;142(5):699-713.


–  CTLA-4andPD-1•  OtherCheckpoints:B7familyandothers•  BeyondCheckpoints:Cos1mulators•  BeyondTcells:NK,DC,Macrophage•  MarkersforcheckpointpathwayinhibiNon

MarkersforCheckpointPathwayInhibiNon

•  Issuesinclinicaltrials–  PredictthepaNentsthatwillbenefitfromthetreatment(tolimitunbeneficialtox)

–  DefinealternaNvetherapeuNcapproachesfornon-respondingpaNents

–  DeterminebestpotenNalassociaNonwithtumortargetedtherapies

–  Definebiomarkerforimmunotherapytreatmentsuspension

S_"?E!CY-+/66.'&!.&!A'&oB$,22"0/22!?%&3!0,&1/+6^!

!"#$%&'(&)*&"+,&-&'%.+&/&0)1&2345&

S/$W+'2.i%$,W!>'+!()/!K+/,($/&(!'>!A'&oB$,22"0/22!?%&3!0,&1/+!

a&/(4!,77!+#$!3,1$(+)K!N-j$61;$!Q$)3/()$8!!>B?Se!&$2%,(!2'.,1/(!/0!.$)3/()$8!>R?E!&/(+#)?!

[O8!3./3/.1/(!)6/.$!`!!e!/0![AHL>!$c3.$))%(4!!+'&/.!6$77)!

!"#$%&'(&)*&"+,&-&'%.+&/&0)1&2345&

ORRaccordingtoPD-L1ExpressioninPaNentswithSolidTumors

RxAnNbody TesNngMethod N PD-L1+RR PD-L1-RRNivolumab1 Manualstaining–5H1

5%cutoffTumorstaining

49 13/3142%

0/180%

Nivolumab2 Dakoautomated5%cutoffTumorstaining

38 7/1741%

3/2114%

MPDL3280A3 AutomatedRocheDxIHC1%cutoffTumorimmunecellstaining

103 13/3636%

9/6713%

Ipi/Nivo4 Dakoautomated5%cutoffTumorstaining

56 8/1457%

17/4240%

MPDL3280A(an1-PD-L1)5

130 26/6043%

8/7011%

From:ImmuntherapyinCancer:FromPrinciplestoPrac1ce1.TopalianSL,etal.NEnglJMed.2012;366:2443-54.2.GrossoJ,etal.ASCO2013.Abstract3016.3.HerbstRS,etal.ASCO2013.Abstract3000.4.SznolM,etal.ASCO2014.LBA9003.5.PowlesT,Nature2014;515:558-562

R&1'3/&/!8/+6%6!K!1/22o_+.8/&!S_"?E!CY-+/66.'&!;-"=/3%2,N'&!

Ob(/7!J!$+!,7?!aO5N!RI>V?!a-)+.,6+!5QaBIIG?!

De0!De0!

S_"?E!S_"?E!S_"?E!S_"?E!

S_"E!S_"E!

S_"E!

S_"?E!S_"?E!

K"1/22!+/1/-('+!

S_"?H!

K!1/22!

ATvJ!R()/+!

S#k]!

K%$'%+!1/22!

#TAr!

#TAr=!

B)-"H!

R&1'3/&.1!-,()b,@!E!

H!

53pa1entsincluded,40%objec1veclinicalresponses,65%witheitherimmuneorclinicalresponseAtthehighestdose,53%clinicalresponsewith80%tumorregression

Nivolumab(AnN-PD1)+Ipilimumab(anN-CTLA4)inadvancedmelanoma

Nivolumab + Ipilimumab in advanced melanoma. Wolchok SL, et al., N Engl J Med. 2013

Progression-free Survival.

Larkin J et al. N Engl J Med 2015;373:23-34

BaselineDensity,LocaNonandProximityofCD8+,PD-1+,PD-L1+andT-cellRepertoirePredictAnN-PD1TreatmentOutcome.

PC Tumeh et al. Nature 515, 568-571 (2014)

Response Progression

Tumor

Invasive margin

PC Tumeh et al. Nature 515, 568-571 (2014)

CD8TCellInfiltraNonIncreasesFollowingAnN-PD1Treatment

CD8TcellsproliferatefollowinganN-PD1treatment

MutaNonalLandscapeofTumorsAccordingtoClinicalBenefitfromIpilimumabTreatment(melanoma).

SnyderAetal.NEnglJMed2014.

MutaNonallandscapedeterminessensiNvitytoPD-1blockadeinnon–smallcelllungcancer

RizviNAetal.Science2015

74

Combinaisons thérapeutiques

Approches explorées1-4

75

Chimiothérapie +

+ Immunothérapie

Radiothérapie +

+ Thérapie ciblée

Immunothérapie active

•  Rationnel, stratégie, séquence ?

1. Drake CG. Ann Oncol 2012;23(suppl 8):viii41-viii46. 2. Hannani D, et al. Cancer J 2011;17:351-8. 3. Ménard C, et al. Cancer Immunol Immunother 2008;57:1579-87. 4. Ribas A, et al. Curr Opin Immunol 2013:25:291-6.

J,.,-$77$!aK!5,'c!5?!C3;;5?!RI>RD!>RI8SSESHE?!

0'$W.&/9!K,+3/(/9!,&9!#$$%&'()/+,-@4!K)/!T%(%+/!'>!S/+6'&,2.i/9!D/9.1.&/!

Documents

Cours du Groupe d’Oncologie de la Société de ...splf.fr/wp-content/uploads/2016/09/Caux_GOLF-Pneumo-Sept-2016-vf.… · Immunothérapie en Cancérologie: checkpoints immunologiques